WithdrawnNo phase
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
Reason given: Time and resource deficiency at the Stockholm CF Center.
Key facts
- Where
- Stockholm, SwedenSee the site
Where in Sweden
- Stockholm CF Center, KArolinska University HospitalStockholm, SwedenNo longer taking part
Trial details
- Who runs it
- Karolinska University Hospital
- Trial code
- NCT02605538
- Record updated
- 18 March 2024
- Original description
CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization has been complete.Read full original descriptionShow less
CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization has been complete.
Inclusion: CF patients not previously immunized against hepatitis A or B; Healthy volunteers not previously immunized against hepatitis A or B; Age over 1 year.
Exclusion: Previously transplanted patients; Previous vaccination with hepatitis vaccine; Known allergy against components in Twinrix (TM).